10-K: CIMG Inc. Reports 433% Revenue Surge Amidst Strategic Shift

CIMG Inc. announced a significant revenue increase of 433.48% to $10.3 million for fiscal year 2025, driven by new health and AI product lines, despite ongoing net losses and a 'going concern' warning.

Summary

• Total revenue for the fiscal year ended September 30, 2025, increased by 433.48% to $10,297,778, up from $1,930,291 in the prior year.
• The Homology of Medicine and Food Series contributed $6,349,252 (61.71%) to total revenue, with exosome eye drops accounting for 60.10% of this series' revenue from a one-time order.
• The Computing Power Product Series generated $3,804,691 (36.94%) in revenue.
• The Maca Series products contributed $144,726 (1.41%) to total revenue.
• Gross profit increased to $125,841 in FY2025 from $32,169 in FY2024, but the gross profit margin decreased to 1.22% from 1.67% due to a higher proportion of lower-margin trading businesses.
• Net loss for FY2025 decreased by 45.50% to $4,890,555, compared to $8,972,735 in FY2024, primarily due to reduced operating expenses.
• Operating expenses decreased by 31.22% to $4,419,331, mainly due to reductions in labor costs, professional fees, and office expenses.
• The company held 500 Bitcoin with a fair value of $57,024,465 as of September 30, 2025, acquired through an equity issuance.
• An accumulated deficit of approximately $87.23 million was reported as of September 30, 2025.
• The company's independent auditors included an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern due to recurring losses and negative working capital of $10,518,757.
• CIMG Inc. regained compliance with Nasdaq Listing Rules for stockholders' equity, timely periodic report filings, and holding an annual meeting by December 4, 2025, but remains subject to a minimum bid price compliance deadline and a Mandatory Panel Monitor through November 14, 2026.
• A 1-for-20 reverse stock split was effected on December 5, 2025, retroactively adjusting all share and per-share data.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the 'going concern' warning, declining gross margins, significant customer/supplier concentration, and goodwill impairment, despite the substantial revenue growth from new, potentially unsustainable, product lines.

Positives

• Total revenue increased significantly by 433.48% to $10.3 million in fiscal year 2025, driven by new product lines.
• Net loss decreased by 45.50% to $4.89 million in fiscal year 2025, indicating improved cost management.
• Operating expenses decreased by 31.22% due to reductions in labor, professional fees, and office expenses.
• Successfully regained compliance with several Nasdaq listing rules, including stockholders' equity, timely filings, and annual meeting requirements.
• Strategic shift into Maca-enhanced products, Homology of Medicine and Food series, and AI Computing Power products has diversified revenue streams.
• Acquired several subsidiaries (Beijing Xilin, Shanghai Huomao, Shenzhen Zhimeng, Braincon Limited) to expand operational footprint and distribution capabilities in Asia.
• Holds significant digital assets, with 500 Bitcoin valued at $57,024,465 as of September 30, 2025, and an additional 230 Bitcoin purchased post-period end.

Negatives

• The company has a history of net losses, with an accumulated deficit of $87.23 million as of September 30, 2025.
• The independent auditor's report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Negative working capital of $10,518,757 as of September 30, 2025, highlights liquidity challenges.
• Gross profit margin decreased to 1.22% from 1.67%, primarily due to the higher proportion of lower-margin trading businesses from newly acquired entities.
• High customer concentration, with two largest customers accounting for 96% of total revenue in FY2025 (Customer A: 60%, Customer B: 36%).
• High supplier concentration, with two largest suppliers accounting for 96.76% of total purchases in FY2025.
• Incurred a full impairment of goodwill totaling $1,859,184 related to the acquisition of Shenzhen Zhimeng Qiyang Technology Co., Ltd., indicating underperformance or adverse changes in the acquired business.
• One-time order for exosome eye drops contributed 60.10% of the Homology of Medicine and Food series revenue, raising questions about the sustainability of this revenue stream.
• Ongoing legal proceedings, including the Kim Litigation ($1,041,216 in monetary damages sought) and the Ex-Directors Lawsuit ($222,062.28 judgment against the company).

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring net losses and negative working capital, requiring additional capital within the next twelve months.
• High concentration of business in Maca Series and Homology of Medicine and Food Series products, making the company vulnerable to changes in consumer preferences, competition, or regulatory developments in these specific markets.
• Reliance on a limited number of significant suppliers (two suppliers contributed 96.76% of total purchases) and customers (two customers accounted for 96% of total revenue) exposes the company to significant operational and financial risks.
• Uncertainty and evolving regulatory landscape in China regarding cybersecurity, data protection, anti-monopoly, and overseas listings, which could lead to government intervention, fines, or operational disruptions.
• Restrictions on foreign exchange and cross-border cash transfers in China may limit the ability of PRC subsidiaries to pay dividends or make other distributions to the parent company.
• Potential for future delisting from Nasdaq if the company fails to comply with the minimum bid price requirement or if the PCAOB is unable to inspect its auditor's work papers related to China operations for two consecutive years.
• Volatility in digital asset prices (Bitcoin) could adversely affect the value of the company's asset holdings and financial condition.
• Risks associated with the early stage of commercialization of new product lines, making future financial results difficult to predict and susceptible to market acceptance and effective marketing.
• Ongoing geopolitical tensions between the United States and China could negatively impact investor sentiment, trade, and the company's business operations.
• Potential for product safety and quality concerns, or mislabeling allegations, to negatively affect consumer confidence, brand reputation, and sales.
• Inability to adequately protect intellectual property rights or being subject to intellectual property infringement claims, which could be expensive and disruptive.
• Increases in labor costs in the PRC could adversely affect profitability.
• Potential for future acquisitions and investments to divert management attention, not perform as expected, or dilute current stockholders.

Future Outlook

The company plans to continue expanding its product offerings, including new Maca-based products and additional items in the Homology of Medicine and Food series, and to offer its Computing Power Product Series to individual users. Geographic expansion is targeted for Asia (China, Southeast Asia) and potentially North America and Europe. Strategies include enhancing brand awareness through digital marketing and influencer partnerships, and strengthening distribution channels via e-commerce and retail partnerships. The company expects to need additional capital to fund planned operations beyond the next twelve months.

Management Comments

• "We are committed to providing healthier and more suitable health and wellness products for Asian customers."
• "We continuously refine our artificial intelligence data-processing templates and enhance the learning capabilities of the modules to deliver more accurate intelligent services across a broad range of industries."
• "CIMG has successfully secured the exclusive distribution and sales rights for all Maca products produced by Jiangsu Kangduoyuan Beverage Co., Ltd., a leading Maca production base in Asia."
• "Through a comprehensive digital marketing strategy, CIMG is optimistic in its ability to achieve sales growth and enhance the Company's enterprise value."
• "Management has evaluated the Company's ability to continue as a going concern by considering its current cash resources, the value of its digital assets, and its expected operating expenses over the next twelve months."
• "Management's plans to alleviate the conditions giving rise to substantial doubt include seeking additional funding through public or private equity financings, equity-linked instruments, or other capital-raising activities."

Industry Context

StockSavvy.ai notes that CIMG Inc.'s strategic pivot aligns with growing global trends in natural health products and the increasing demand for AI-driven solutions. The projected CAGR of over 4.2% for the global Maca market and 4.5% for Medicine and Food Homologous Products, alongside an 18% CAGR for the global AI hardware market, suggests the company is targeting high-growth sectors. However, the intense competition in the 'massive health industry' and the entry of traditional technology industries into AI pose significant challenges. The company's focus on digital marketing and local partnerships in Asia is a common strategy for market penetration in these competitive environments.

Comparison to Industry Standards

• The global Maca market is projected to grow at a CAGR of more than 4.2% from 2026 to 2035, exceeding approximately $100 million by 2035. CIMG's Maca Series contributed only $144,726 to revenue in FY2025, indicating a very small market share in this growing segment.
• The global Medicine and Food Homologous Products market is expected to grow from $1.07 billion in 2024 to $1.45 billion by 2031, representing a CAGR of 4.5%. CIMG's Homology of Medicine and Food Series generated $6,349,252 in FY2025, suggesting a more substantial, though still niche, presence in this market, but with a significant portion from a one-time order.
• The global artificial intelligence hardware market is projected to grow from $66.8 billion in 2025 to $296.3 billion in 2034, representing a CAGR of 18%. CIMG's Computing Power Product Series revenue of $3,804,691 in FY2025 positions it as a very small player in a rapidly expanding market, with significant growth potential if it can scale effectively.

Management Changes

Corporate Governance

Legal Proceedings

• The Kim Litigation: Mr. Sooncha Kim filed a complaint on October 3, 2024, alleging breach of a Convertible Note and Warrant Purchase Agreement, seeking $1,041,216 in monetary damages and specific performance. The company's motion for preliminary injunction was denied on February 13, 2025, and discovery is ongoing.
• The Ex-Directors Lawsuit: Former directors filed a complaint on March 10, 2025, for unpaid directors' fees and expenses. A default judgment was entered against the company on August 22, 2025, for $58,920.34, which was later amended on November 21, 2025, to an aggregate of $222,062.28, including prejudgment interest and costs.

Related Party Transactions

• Loans advanced to Xilin Online (Beijing) E-commerce Co., Ltd. by Wanhai Liu ($12,262) and Tianyong Lv ($12,754) in FY2025.
• Loan advanced to Shenzhen Zhimeng Qiyang Technology Co., Ltd. by Shengqing Li ($185,765) in FY2025.
• Loans advanced to Shanghai Huomao Cultural Development Co., Ltd. ($56) and Guizhou Zhutai Huomao Liquor Industry Co., Ltd. ($637) by Hongfang Xie in FY2025.
• Loan advanced from Zhongyan Shangyue Technology Co., Ltd. to Wenlong Tong ($(18,662)) in FY2025.
• Loan advanced from Wewin Technology LLC to Wenwen Yu ($(73,795)) in FY2025 (compared to $7,500 in FY2024).
• Convertible notes with Metaverse Intelligence Tech Ltd. (an entity whose owner is a director of Wewin Technology LLC) totaling $3,693,041 issued in FY2025 (compared to $300,000 in FY2024).

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises and potential future equity issuances to address liquidity concerns and fund growth.
• Shareholders are exposed to substantial risk due to the 'going concern' warning and the volatility of the company's stock price, which could decline or become worthless.
• Employees may experience uncertainty due to the company's financial condition and the need for additional capital, though management aims to retain skilled personnel.
• Customers may benefit from expanded product offerings in health and AI, but high customer concentration poses a risk if key relationships are disrupted.
• Suppliers face risks due to high supplier concentration, as disruptions or changes in terms with major suppliers could impact the company's ability to source products.
• Creditors, particularly holders of convertible notes, face risks related to the company's ability to repay debt, especially given the ongoing litigation and 'going concern' issues.

Next Steps

• Continue developing a diverse range of Maca-based products, including new product lines like Maca Peptide Coffee, Maca-Noni, Maca Wine, and Maca Purified Powder.
• Expand product offerings in the Homology of Medicine and Food series and other functional food and beverage items.
• Gradually develop and offer the Computing Power Product Series to individual users.
• Increase global presence, particularly in Asia (China, Southeast Asia) and explore opportunities in North America and Europe.
• Significantly increase marketing efforts, including digital marketing initiatives, social media influencer partnerships, and sport champion collaborations, to boost brand recognition.
• Strengthen and diversify distribution channels by growing e-commerce platforms and increasing partnerships with retailers and international distributors.
• Seek additional capital through public or private equity offerings, equity-linked instruments, or other capital-raising activities to fund operations and address going concern doubts.
• Resolve ongoing legal proceedings, including the Kim Litigation and the Ex-Directors Lawsuit.
• Monitor and maintain compliance with Nasdaq listing rules, particularly the minimum bid price requirement, through November 14, 2026.
• Procure new raw materials for Maca products that comply with updated regulatory requirements, following the disposal of historical inventories.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the 'going concern' warning from its auditors, recurring net losses, and negative working capital. While revenue growth is substantial, it's driven by new, potentially unstable, product lines with declining gross margins and includes a significant one-time order. High customer and supplier concentration, coupled with a goodwill impairment, indicate significant operational risks. Ongoing legal proceedings and the persistent Nasdaq minimum bid price deficiency further compound the uncertainty. These factors collectively suggest a high probability of continued financial instability and potential for significant capital loss for investors.

Keywords

Maca products, health and wellness, AI computing power, digital marketing, e-commerce, China market, Nasdaq listing, SEC filing, going concern, Bitcoin holdings, supply chain risk, customer concentration, regulatory risk China, corporate governance, equity incentive plan